Opthea To Participate In Citi 2024 Global Healthcare Conference

(MENAFN- GlobeNewsWire - Nasdaq) MELBOURNE, Australia and PRINCETON, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT,“Opthea”, the“Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Fred Guerard, PharmD, Chief Executive Officer, will host one-on-one meetings with investors and participate in a panel presentation during the Citi 2024 Global Healthcare conference on December 5, 2024 in Miami, Florida.

Details are as follows:

Panel:	Eyes Wide Open on Ophthalmology
Presenter:	Frederic Guerard, PharmD, CEO, Opthea
Date:	Thursday, December 5, 2024, 1:45 PM ET

The webcast will be accessible on the“Events & Presentations” section of the Company's website at

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636 , and ShORe, NCT04757610 ) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at and follow us on X and LinkedIn .

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: ...
Phone: 617-430-7579

Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: ...

Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: ... Web:
Source: Opthea Limited

MENAFN25112024004107003653ID1108922275